[A18-44] Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V
Last updated 01.10.2018
Project no.:
A18-44
Commission:
Commission awarded on 29.06.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with advanced (unresectable or metastatic) melanoma
Treatment-naive patients with BRAF V600 mutant tumour and pretreated patients: added benefit not proven. Treatment-naive patients with BRAF V600 WT tumour: indication of lesser benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-12 | Ipilimumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-12 | Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A13-44 | Ipilimumab (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A12-07 | Ipilimumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A20-116 | Ipilimumab (non-small cell lung cancer, combination with nivolumab) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-12-20 A G-BA decision was published.